-
Mashup Score: 0From AACR 2024 - 3 day(s) ago
Nature Reviews Clinical Oncology – From AACR 2024
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Nature Reviews Clinical Oncology – ALND can be safely omitted for patients with sentinel-node macrometastases
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3FDA approves alectinib as adjuvant treatment - 10 day(s) ago
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 76Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma - 13 day(s) ago
Nature Reviews Clinical Oncology – T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 59Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials - 18 day(s) ago
Nature Reviews Clinical Oncology – The benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer types,…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 27
Nature Reviews Clinical Oncology – Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer - 1 month(s) ago
Nature Reviews Clinical Oncology – Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Oncology Burst - 1 month(s) ago
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4A new standard of care for advanced-stage urothelial carcinoma - 1 month(s) ago
Nature Reviews Clinical Oncology – A new standard of care for advanced-stage urothelial carcinoma
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
In a Research Highlight now published online, we discuss some clinical studies presented #AACR24 https://t.co/Qmq9iPwFGI https://t.co/DOVHuisNS2